Online inquiry

IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13983MR)

This product GTTS-WQ13983MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13983MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11243MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ8574MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ15352MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ6663MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ5381MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ12631MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15803MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ15876MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW